Cargando…

Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer

OBJECTIVE: Evidence demonstrates that the immune microenvironment is extensively associated with chemotherapy response of ovarian cancer (OV). Herein, this study is aimed at establishing a cisplatin response prediction model for OV on the basis of immune genes. METHODS: The expression profiles of ci...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Ying, Yang, Na, Li, Gang, Yin, Xiurong, Dong, Lixia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133897/
https://www.ncbi.nlm.nih.gov/pubmed/35647204
http://dx.doi.org/10.1155/2022/4379216
_version_ 1784713675938988032
author Guo, Ying
Yang, Na
Li, Gang
Yin, Xiurong
Dong, Lixia
author_facet Guo, Ying
Yang, Na
Li, Gang
Yin, Xiurong
Dong, Lixia
author_sort Guo, Ying
collection PubMed
description OBJECTIVE: Evidence demonstrates that the immune microenvironment is extensively associated with chemotherapy response of ovarian cancer (OV). Herein, this study is aimed at establishing a cisplatin response prediction model for OV on the basis of immune genes. METHODS: The expression profiles of cisplatin-sensitive and cisplatin-resistant OV specimens were integrated from multiple public datasets. The abundance scores of 22 immune cells were estimated with CIBERSORT algorithm. Differentially expressed immune genes (DEGs) were determined between cisplatin-sensitive and cisplatin-resistant groups. Thereafter, a cisplatin response model was constructed based on prognostic DEGs with logistic regression analysis. The prediction performance was validated in independent cohorts. The possible relationships between the model and immunotherapy were then assessed. RESULTS: Treg scores were significantly decreased in cisplatin-resistant than cisplatin-sensitive OV specimens, with the opposite results for naïve B cells and activated dendritic cells. Fourteen prognostic DEGs were identified and used to develop a cisplatin-response model. The response scores, estimated by the model, showed favorable performance in discriminating cisplatin-response and nonresponse samples. The response scores also presented significantly negative correlations with three well-known cisplatin-resistant pathways and a positive correlation with the expression of CD274 (PD-L1). Moreover, the decreased CD27 expression was observed in cisplatin-resistant groups, and OV specimens with higher CD27 expressions were more sensitive to cisplatin treatment. CONCLUSION: Altogether, our findings proposed a cisplatin response prediction model and identified CD27 that might be involved in cisplatin resistance. Further investigations suggested that CD27 could be a promising immunotherapeutic target for cisplatin-resistant subset of OV.
format Online
Article
Text
id pubmed-9133897
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-91338972022-05-27 Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer Guo, Ying Yang, Na Li, Gang Yin, Xiurong Dong, Lixia J Immunol Res Research Article OBJECTIVE: Evidence demonstrates that the immune microenvironment is extensively associated with chemotherapy response of ovarian cancer (OV). Herein, this study is aimed at establishing a cisplatin response prediction model for OV on the basis of immune genes. METHODS: The expression profiles of cisplatin-sensitive and cisplatin-resistant OV specimens were integrated from multiple public datasets. The abundance scores of 22 immune cells were estimated with CIBERSORT algorithm. Differentially expressed immune genes (DEGs) were determined between cisplatin-sensitive and cisplatin-resistant groups. Thereafter, a cisplatin response model was constructed based on prognostic DEGs with logistic regression analysis. The prediction performance was validated in independent cohorts. The possible relationships between the model and immunotherapy were then assessed. RESULTS: Treg scores were significantly decreased in cisplatin-resistant than cisplatin-sensitive OV specimens, with the opposite results for naïve B cells and activated dendritic cells. Fourteen prognostic DEGs were identified and used to develop a cisplatin-response model. The response scores, estimated by the model, showed favorable performance in discriminating cisplatin-response and nonresponse samples. The response scores also presented significantly negative correlations with three well-known cisplatin-resistant pathways and a positive correlation with the expression of CD274 (PD-L1). Moreover, the decreased CD27 expression was observed in cisplatin-resistant groups, and OV specimens with higher CD27 expressions were more sensitive to cisplatin treatment. CONCLUSION: Altogether, our findings proposed a cisplatin response prediction model and identified CD27 that might be involved in cisplatin resistance. Further investigations suggested that CD27 could be a promising immunotherapeutic target for cisplatin-resistant subset of OV. Hindawi 2022-05-18 /pmc/articles/PMC9133897/ /pubmed/35647204 http://dx.doi.org/10.1155/2022/4379216 Text en Copyright © 2022 Ying Guo et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Guo, Ying
Yang, Na
Li, Gang
Yin, Xiurong
Dong, Lixia
Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer
title Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer
title_full Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer
title_fullStr Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer
title_full_unstemmed Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer
title_short Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer
title_sort identification of an immune gene-based cisplatin response model and cd27 as a therapeutic target against cisplatin resistance for ovarian cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133897/
https://www.ncbi.nlm.nih.gov/pubmed/35647204
http://dx.doi.org/10.1155/2022/4379216
work_keys_str_mv AT guoying identificationofanimmunegenebasedcisplatinresponsemodelandcd27asatherapeutictargetagainstcisplatinresistanceforovariancancer
AT yangna identificationofanimmunegenebasedcisplatinresponsemodelandcd27asatherapeutictargetagainstcisplatinresistanceforovariancancer
AT ligang identificationofanimmunegenebasedcisplatinresponsemodelandcd27asatherapeutictargetagainstcisplatinresistanceforovariancancer
AT yinxiurong identificationofanimmunegenebasedcisplatinresponsemodelandcd27asatherapeutictargetagainstcisplatinresistanceforovariancancer
AT donglixia identificationofanimmunegenebasedcisplatinresponsemodelandcd27asatherapeutictargetagainstcisplatinresistanceforovariancancer